The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Ranibizumab for Neovascular Age-Related Macular Degeneration
Open accessAbstract
BACKGROUND: Ranibizumab--a recombinant, humanized, monoclonal antibody Fab that neutralizes all active forms of vascular endothelial growth factor A--has been evaluated for the treatment of neovascular age-related macular degeneration. METHODS: In this multicenter, 2-year, double-blind, sham-controlled study, we randomly assigned patients with age-related macular degeneration with either minimally classic or occult (with no classic lesions) choroidal neovascularization to receive 24 monthly intravitreal injections of ranibizumab (either 0.3 mg or 0.5 mg) or sham injections. The primary end point was the proportion of patients losing fewer than 15 letters from baseline visual acuity at 12 months. RESULTS: We enrolled 716 patients in the study. At 12 months, 94.5% of the group given 0.3 mg of ranibizumab and 94.6% of those given 0.5 mg lost fewer than 15 letters, as compared with 62.2% of patients receiving sham injections (P<0.001 for both comparisons). Visual acuity improved by 15 or more letters in 24.8% of the 0.3-mg group and 33.8% of the 0.5-mg group, as compared with 5.0% of the sham-injection group (P<0.001 for both doses). Mean increases in visual acuity were 6.5 letters in the 0.3-mg group and 7.2 letters in the 0.5-mg group, as compared with a decrease of 10.4 letters in the sham-injection group (P<0.001 for both comparisons). The benefit in visual acuity was maintained at 24 months. During 24 months, presumed endophthalmitis was identified in five patients (1.0%) and serious uveitis in six patients (1.3%) given ranibizumab. CONCLUSIONS: Intravitreal administration of ranibizumab for 2 years prevented vision loss and improved mean visual acuity, with low rates of serious adverse events, in patients with minimally classic or occult (with no classic lesions) choroidal neovascularization secondary to age-related macular degeneration. (ClinicalTrials.gov number, NCT00056836 [ClinicalTrials.gov].).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Ranibizumab anti-Fab immunoreactivity in treatment-naïve patients was between 0–0.9% in the MARINA and ANCHOR trials [30, 31].”
From Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review (2021) · cites this paper as [30]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The MARINA and ANCHOR trials with ranibizumab showed an incidence of 0.05% [30, 31], and a subsequent comparison study of ranibizumab and bevacizumab for neovascular AMD reported rates of 0.16% for ranibizumab and 0.5% for bevacizumab [32].”
From Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review (2021) · cites this paper as [30]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Regardless of anti-VEGF agent, pre-treatment ADA titers have not been shown to have any clinically relevant difference in BCVA outcomes [30, 33, 41, 43].”
From Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review (2021) · cites this paper as [30]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Repeated intravitreal (IVT) injections of anti-VEGF therapies effectively slow vision loss in the majority of treatment-compliant patients with wet AMD. 7 – 13”
From Design and Characterization of a Novel Intravitreal Dual-Transgene Genetic Medicine for Neovascular Retinopathies (2024) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the ANCHOR and MARINA studies, 8-14% of eyes gained 415 letters during months 4 to 12. [22][23][24]”
From Defining response to anti-VEGF therapies in neovascular AMD (2015) · cites this paper as [22]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It is now accepted that the best outcomes with anti-VEGF therapies in n-AMD are achieved with regular dosing at specific intervals, usually monthly, as demonstrated in the pivotal trials of ranibizumab, and sometimes two monthly in the first year with aflibercept after the ' three monthly initiation doses'.[22][23][24][25]”
From Defining response to anti-VEGF therapies in neovascular AMD (2015) · cites this paper as [22]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, this initial response at month 4 is not always predictive of long-term VA gains, as a proportion of such eyes continue to accrue gains in vision even after month 4 as in the ANCHOR and MARINA studies, 22,24 HARBOR study 30 and subsequent case series.31”
From Defining response to anti-VEGF therapies in neovascular AMD (2015) · cites this paper as [22]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Other major anti-VEGF clinical trials excluded such patients.18,19,20”
From Development and Course of Scars in the Comparison of Age-Related Macular Degeneration Treatments Trials (2018) · cites this paper as [19]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“However, such lesions may be difficult to categorise as there are a group of 'delayed responders' who will not gain vision until well after 3 and sometimes not until after 12 months.22,24”
From Defining response to anti-VEGF therapies in neovascular AMD (2015) · cites this paper as [22]
Experimental — accuracy not yet measuredIn the citing paper
“In CATT and all randomized clinical trials of anti-VEGF treatment for neovascular AMD, most of the improvement in mean visual acuity from baseline occurred within the first 3 to 6 months with little erosion of the benefit through 2 years when a fixed schedule of monthly (ranibizumab, bevacizumab, aflibercept) or bi-monthly (aflibercept) treatment was maintained.1,7,9,17,34”
From Five-Year Outcomes with Anti–Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration (2016) · cites this paper as [1]
In the citing paper
“was associated with a remarkable proportion of patients with an improvement in vision”
From Age-related macular degeneration (2008) · cites this paper as [164]
In the citing paper
“Ranibizumab is a fragment of a monoclonal antibody that binds to and inhibits all forms of VEGF-A.164,165”
From Age-related macular degeneration (2008) · cites this paper as [164]
In the citing paper
“This drug, when injected intravitreally on a monthly basis, prevented vision loss”
From Age-related macular degeneration (2008) · cites this paper as [164]
In the citing paper
“These benefits persisted through 24 months of follow-up.”
From Age-related macular degeneration (2008) · cites this paper as [164]
In the citing paper
“Mean differences in visual acuity score in the treated and control groups were also impressive, with a mean increase of seven letters in the treated group compared with a mean decrease of 10 letters in the placebo group (p<0·001).”
From Age-related macular degeneration (2008) · cites this paper as [164]
In the citing paper
“At 12 months, 95% of patients given ranibizumab 0·5 mg lost fewer than 15 letters (three lines of vision) compared with 62% of the placebo group (p<0·001).”
From Age-related macular degeneration (2008) · cites this paper as [164]
In the citing paper
“for the first time with any treatment for age-related macular degeneration, was associated with a remarkable proportion of patients with an improvement in vision”
From Age-related macular degeneration (2008) · cites this paper as [164]
In the citing paper
“Additionally, 34% of this group improved by 15 or more letters of vision compared with the 5% in the placebo group (p<0·001).”
From Age-related macular degeneration (2008) · cites this paper as [164]
In the citing paper
“The adverse effects included endophthalmitis (1%) and serious uveitis (1%).”
From Age-related macular degeneration (2008) · cites this paper as [164]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Altman, R., Carreras, L., Díaz, R. S., Figueroa, E. B., Paolasso, E., Parodi, J. C., Cade, J. F., Donnan, G. A., Eadie, M. J., Gavaghan, T. P., et al. (1994) · BMJ · doi:10.1136/bmj.308.6921.81 · Cited by 4,204
Global data on visual impairment in the year 2002.
(2004) · Europe PMC (PubMed Central) · Cited by 4,157
Vascular Endothelial Growth Factor: Basic Science and Clinical Progress
Ferrara, N. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0027 · Cited by 3,788
Some Methods for Strengthening the Common χ 2 Tests
Cochran, W. G. (1954) · Biometrics · doi:10.2307/3001616 · Cited by 3,718
Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062655 · Cited by 3,522
Self-citationAltman, R., Carreras, L., Díaz, R. S., Figueroa, E. B., Paolasso, E., Parodi, J. C., Cade, J. F., Donnan, G. A., Eadie, M. J., Gavaghan, T. P., et al. (1994) · Cited by 3,322
Prevalence of Age-Related Macular Degeneration in the United States
The Eye Diseases Prevalence Research Group* (2004) · Archives of Ophthalmology · doi:10.1001/archopht.122.4.564 · Cited by 2,774
Pegaptanib for neovascular age-related macular degeneration
Gragoudas, E. S., Adamis, A. P., Cunningham, E. T., Feinsod, M., & Guyer, D. R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042760 · Cited by 2,337
Treatment of Age-related Macular Degeneration With Photodynamic Therapy (TAP) Study Group (1999) · Archives of Ophthalmology · doi:10.1001/archopht.117.10.1329 · Cited by 2,192
Flagged first, then by citations
Research works printed but not linked: 5
- Resnikoff S, 2004, Bull World Health Organ, 82, 844
- Bressler NM, 2001, Arch Ophthalmol, 119, 198
- Lopez PF, 1996, Invest Ophthalmol Vis Sci, 37, 855
- Kvanta A, 1996, Invest Ophthalmol Vis Sci, 37, 1929
- Grading of vitreous cells. In: Nussenblatt RB, Whitcup SM, Palestine AG. Uveitis: fundamentals and clinical practice. 2nd ed. New York: Mosby, 1996:64.
Cited by
Sorted by citations
Items 101–200 of 1,051
Association Between C-Reactive Protein and Age-Related Macular Degeneration
Keenan, T. D. L., & Chew, E. Y. (2017) · International Journal of Research in Medical Sciences · doi:10.1001/jamaophthalmol.2017.2210 · Cited by 378
Incidence of Legal Blindness From Age-Related Macular Degeneration in Denmark: Year 2000 to 2010
Bloch, S. B., Larsen, M., & Munch, I. C. (2012) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2011.10.016 · Cited by 377
Mettu, P. S., Allingham, M. J., & Cousins, S. W. (2021) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2020.100906 · Cited by 370
Bourne, R., Jonas, J. B., Bron, A. M., Cicinelli, M. V., Das, A., Flaxman, S. R., Friedman, D. S., Keeffe, J. E., Kempen, J. H., Leasher, J. L., et al. (2018) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2017-311258 · Cited by 370
Age-Related Macular Degeneration Preferred Practice Pattern®
Flaxel, C. J., Adelman, R. A., Bailey, S. T., Fawzi, A. A., Lim, J. I., Vemulakonda, G. A., & Ying, G. (2019) · Ophthalmology · doi:10.1016/j.ophtha.2019.09.024 · Cited by 367
Kaiser, P. K., Brown, D. M., Zhang, K., Hudson, H. L., Holz, F. G., Shapiro, H., Schneider, S., & Acharya, N. R. (2007) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2007.08.012 · Cited by 361
Self-citationSun, X., Yang, S., & Zhao, J. (2016) · Drug Design Development and Therapy · doi:10.2147/dddt.s97653 · Cited by 358
Singer, M. A., Awh, C. C., Sadda, S., Freeman, W. R., Antoszyk, A. N., Wong, P., & Tuomi, L. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2011.12.016 · Cited by 356
Defining response to anti-VEGF therapies in neovascular AMD
Amoaku, W. M., Chakravarthy, U., Gale, R., Gavin, M., Ghanchi, F., Gibson, J., Harding, S., Johnston, R. L., Kelly, S., Lotery, A., et al. (2015) · Eye · doi:10.1038/eye.2015.48 · Cited by 355
Cheung, N., & Wong, T. Y. (2007) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2006.12.003 · Cited by 355
Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease.
Goel, S., Wong, A. H.-K., & Jain, R. K. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006486 · Cited by 352
Boyer, D. S., Heier, J. S., Brown, D. M., Francom, S. F., Ianchulev, T., & Rubio, R. G. (2009) · Ophthalmology · doi:10.1016/j.ophtha.2009.05.024 · Cited by 351
Self-citationVEGF-A: a critical regulator of blood vessel growth
Ferrara, N. (2009) · European Cytokine Network · doi:10.1684/ecn.2009.0170 · Cited by 346
Age-related macular degeneration and polypoidal choroidal vasculopathy in Asians
Wong, C. W., Yanagi, Y., Lee, W., Ogura, Y., Yeo, I. Y. S., Wong, T. Y., & Cheung, C. M. G. (2016) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2016.04.002 · Cited by 345
Regulation of angiogenesis and choroidal neovascularization by members of microRNA-23∼27∼24 clusters
Zhou, Q., Gallagher, R., Ufret-Vincenty, R., Li, X., Olson, E. N., & Wang, S. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1105254108 · Cited by 341
Markers of Response for the Antiangiogenic Agent Bevacizumab
Lambrechts, D., Lenz, H., de Haas, S., Carmeliet, P., & Scherer, S. J. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.2762 · Cited by 341
Targeting angiogenesis in oncology, ophthalmology and beyond
Cao, Y., Langer, R., & Ferrara, N. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00671-z · Cited by 339
Nanoparticle diffusion in, and microrheology of, the bovine vitreous ex vivo
Xu, Q., Boylan, N. J., Suk, J. S., Wang, Y.-Y., Nance, E. A., Yang, J., McDonnell, P. J., Cone, R. A., Duh, E. J., & Hanes, J. S. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.01.018 · Cited by 339
Risk of Scar in the Comparison of Age-related Macular Degeneration Treatments Trials
Daniel, E., Toth, C. A., Grunwald, J. E., Jaffe, G. J., Martin, D. F., Fine, S. L., Huang, J., Ying, G.-S., Hagstrom, S. A., Winter, K., et al. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2013.10.019 · Cited by 335
Targeted deletion of Vegfa in adult mice induces vision loss
Kurihara, T., Westenskow, P. D., Bravo, S., Aguilar, E., & Friedlander, M. (2012) · Journal of Clinical Investigation · doi:10.1172/jci65157 · Cited by 331
Campochiaro, P. A., Hafiz, G., Shah, S. M., Nguyen, Q. D., Ying, H. S.-C., Diana, V., Quinlan, E., Zimmer-Galler, I. E., Haller, J. A., Solomon, S. D., et al. (2008) · Molecular Therapy · doi:10.1038/mt.2008.10 · Cited by 326
Three-Year Outcomes of Individualized Ranibizumab Treatment in Patients with Diabetic Macular Edema
Schmidt-Erfurth, U. M., Lang, G. E., Holz, F. G., Schlingemann, R. O., Lanzetta, P., Massin, P., Gerstner, O., Bouazza, A. S., Shen, H., Osborne, A. R., et al. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2013.11.041 · Cited by 324
Nanotechnology-based ocular drug delivery systems: recent advances and future prospects
Li, S., Chen, L., & Fu, Y. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-01992-2 · Cited by 323
Age‐related Macular Degeneration (AMD)
(2008) · Springer eBooks · doi:10.1007/978-3-540-38918-7_5059 · Cited by 322
Ophthalmic drug discovery: novel targets and mechanisms for retinal diseases and glaucoma
Zhang, K., Zhang, L., & Weinreb, R. N. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3745 · Cited by 320
Guymer, R. H., Markey, C. M., McAllister, I. L., Gillies, M. C., Hunyor, A. P., Arnold, J. J., Chang, A., Syed, A., Broadhead, G., Pham, T., et al. (2019) · Ophthalmology · doi:10.1016/j.ophtha.2018.11.025 · Cited by 317
Kaiser, P. K. (2009) · PubMed Central · Cited by 315
Self-citationYing, G.-S., Huang, J., Maguire, M. G., Jaffe, G. J., Grunwald, J. E., Toth, C., Daniel, E., Klein, M., Pieramici, D., Wells, J., et al. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2012.07.042 · Cited by 305
Fibrosis and diseases of the eye
Friedlander, M. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31030 · Cited by 306
Heier, J. S. (2006) · Archives of Ophthalmology · doi:10.1001/archopht.124.11.1532 · Cited by 304
Self-citationSystemic and Ocular Safety of Intravitreal Anti-VEGF Therapies for Ocular Neovascular Disease
Tolentino, M. J. (2011) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2010.08.006 · Cited by 303
Wong, T. Y., & Scott, I. U. (2010) · New England Journal of Medicine · doi:10.1056/nejmcp1003934 · Cited by 303
Ranibizumab: Phase III clinical trial results.
Rosenfeld, P. J., Rich, R., & Lalwani, G. A. (2006) · PubMed · doi:10.1016/j.ohc.2006.05.009 · Cited by 301
Self-citationBennett, R. E., Robbins, A. B., Hu, M., Cao, X., Betensky, R. A., Clark, T., Das, S., & Hyman, B. T. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1710329115 · Cited by 299
The Genetics of Age-Related Macular Degeneration: A Review of Progress to Date
Haddad, S., Chen, C. A., Santangelo, S. L., & Seddon, J. M. (2006) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2006.05.001 · Cited by 299
Mitchell, P. L. R., Jf, K., Lanzetta, P., Holz, F. G., Prünte, C. F., Schmidt-Erfurth, U. M., Tano, Y., & Wolf, S. (2009) · British Journal of Ophthalmology · doi:10.1136/bjo.2009.159160 · Cited by 299
2018 Update on Intravitreal Injections: Euretina Expert Consensus Recommendations
Grzybowski, A., Told, R., Sacu, S., Bandello, F., Moisseiev, E., Loewenstein, A., Schmidt-Erfurth, U., & on behalf of the Euretina Board (2018) · Ophthalmologica · doi:10.1159/000486145 · Cited by 297
Chun, D. W., Heier, J. S., Topping, T. M., Duker, J. S., & Bankert, J. M. (2006) · Ophthalmology · doi:10.1016/j.ophtha.2006.04.033 · Cited by 295
Self-citationThe Diagnosis and Treatment of Age-Related Macular Degeneration
Stahl, A. (2020) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2020.0513 · Cited by 296
Jaffe, G. J., Martin, D. F., Toth, C. A., Daniel, E., Maguire, M. G., Ying, G.-S., Grunwald, J. E., & Huang, J. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2013.01.073 · Cited by 294
RPE necroptosis in response to oxidative stress and in AMD
Hanus, J., Anderson, C. A., & Wang, S. (2015) · Ageing Research Reviews · doi:10.1016/j.arr.2015.09.002 · Cited by 293
Complications of intravitreal injections
Sampat, K. M., & Garg, S. J. (2010) · Current Opinion in Ophthalmology · doi:10.1097/icu.0b013e328338679a · Cited by 291
Evaluation of Age-related Macular Degeneration With Optical Coherence Tomography
Keane, P. A., Patel, P. J., Liakopoulos, S., Heussen, F. M., Sadda, S. R., & Tufail, A. (2012) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2012.01.006 · Cited by 291
RETOUCH: The Retinal OCT Fluid Detection and Segmentation Benchmark and Challenge
Bogunović, H., Venhuizen, F. G., Riedl, S., Apostolopoulos, S., Bab‐Hadiashar, A., Bağcı, U., Beg, M. F., Bekalo, L., Chen, Q., Ciller, C., et al. (2019) · IEEE Transactions on Medical Imaging · doi:10.1109/tmi.2019.2901398 · Cited by 287
Handa, J. T., Rickman, C. B., Dick, A. D., Gorin, M. B., Miller, J. W., Toth, C. A., Ueffing, M., Zarbin, M. A., & Farrer, L. A. (2019) · Nature Communications · doi:10.1038/s41467-019-11262-1 · Cited by 285
(2014) · Ophthalmology · doi:10.1016/j.ophtha.2013.11.031 · Cited by 283
The Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration
Campochiaro, P. A., Marcus, D. M., Awh, C. C., Regillo, C. D., Adamis, A. P., Bantseev, V., Chiang, Y. L., Ehrlich, J. S., Erickson, S. R., Hanley, W. D., et al. (2019) · Ophthalmology · doi:10.1016/j.ophtha.2019.03.036 · Cited by 282
Diabetic retinopathy and systemic vascular complications
Cheung, N., & Wong, T. Y. (2007) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2007.12.001 · Cited by 280
Lee, W. K., Iida, T., Ogura, Y., Chen, S., Wong, T. Y., Mitchell, P., Cheung, C. M. G., Zhang, Z., Leal, S., Ishibashi, T., et al. (2018) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2018.1804 · Cited by 280
Anti-vascular endothelial growth factor for neovascular age-related macular degeneration
Solomon, S. D., Lindsley, K. B., Vedula, S. S., Krzystolik, M. G., & Hawkins, B. S. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005139.pub4 · Cited by 280
Chong, E. W.-T. (2008) · Archives of Ophthalmology · doi:10.1001/archopht.126.6.826 · Cited by 279
Updates on the Epidemiology of Age-Related Macular Degeneration
Jonas, J. B., Cheung, C. M. G., & Panda‐Jonas, S. (2017) · Asia-Pacific Journal of Ophthalmology · doi:10.22608/apo.2017251 · Cited by 278
Wykoff, C. C., Croft, D. E., Brown, D. M., Wang, R., Payne, J. F., Clark, L., Abdelfattah, N. S., & Sadda, S. R. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2015.08.009 · Cited by 277
Self-citationA review of clinical trials of anti-VEGF agents for diabetic retinopathy
Nicholson, B. P., & SCHACHAT, A. P. (2010) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-010-1315-z · Cited by 275
A Treat and Extend Regimen Using Ranibizumab for Neovascular Age-Related Macular Degeneration
Gupta, O. P., Shienbaum, G., Patel, A. H., Fecarotta, C., Kaiser, R. S., & Regillo, C. D. (2010) · Ophthalmology · doi:10.1016/j.ophtha.2010.02.032 · Cited by 272
A review of anti-VEGF agents for proliferative diabetic retinopathy
Osaadon, P., Fagan, X. J., Lifshitz, T., & Levy, J. (2014) · Eye · doi:10.1038/eye.2014.13 · Cited by 272
Optical coherence tomography angiography in retinal diseases
Chalam, K. V., & Sambhav, K. (2016) · Journal of Ophthalmic and Vision Research · doi:10.4103/2008-322x.180709 · Cited by 270
Mehta, H., Tufail, A., Daïen, V., Lee, A., Nguyen, V., Ozturk, M., Barthelmes, D., & Gillies, M. C. (2018) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2017.12.002 · Cited by 272
Treat-and-Extend versus Monthly Regimen in Neovascular Age-Related Macular Degeneration
da Silva, R. M., Berta, A., Larsen, M., Macfadden, W., Feller, C., & Monés, J. (2017) · Ophthalmology · doi:10.1016/j.ophtha.2017.07.014 · Cited by 267
Report from the NEI/FDA Ophthalmic Clinical Trial Design and Endpoints Symposium *
Csaky, K. G., Richman, E. A., & Ferris, F. L. (2008) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.07-1132 · Cited by 265
POLYPOIDAL CHOROIDAL VASCULOPATHY: Evidence-Based Guidelines for Clinical Diagnosis and Treatment
Koh, A. H. C., Chen, L.-J., Chen, S.-J., Chen, Y., Giridhar, A., Iida, T., Kim, H., Lai, T. Y. Y., Lee, W. K., Li, X., et al. (2013) · Retina · doi:10.1097/iae.0b013e3182852446 · Cited by 265
Mitochondrial DNA Damage as a Potential Mechanism for Age-Related Macular Degeneration
Karunadharma, P. P., Nordgaard, C. L., Olsen, T. W., & Ferrington, D. A. (2010) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.10-5429 · Cited by 265
Kodjikian, L., Souied, E. H., Mimoun, G., Mauget‐Faÿsse, M., Béhar‐Cohen, F., Decullier, É., Huot, L., & Aulagner, G. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2013.06.020 · Cited by 265
Roisman, L., Zhang, Q., Wang, R. K., Gregori, G., Zhang, A., Chen, C., Durbin, M. K., An, L., Stetson, P. F., Robbins, G., et al. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2016.01.044 · Cited by 264
Self-citationCCR3 is a target for age-related macular degeneration diagnosis and therapy
Takeda, A., Baffi, J. Z., Kleinman, M. E., Cho, W. G., Nozaki, M., Yamada, K., Kaneko, H., Albuquerque, R. J. C., Dridi, S., Saito, K., et al. (2009) · Nature · doi:10.1038/nature08151 · Cited by 263
Stem cells in retinal regeneration: past, present and future
Ramsden, C. M., Powner, M. B., Carr, A. F., Smart, M. J. K., da Cruz, L., & Coffey, P. J. (2013) · Development · doi:10.1242/dev.092270 · Cited by 259
INTRAVITREAL INJECTION OF THERAPEUTIC AGENTS
PEYMAN, G. A., LAD, E. M., & MOSHFEGHI, D. M. (2009) · Retina · doi:10.1097/iae.0b013e3181a94f01 · Cited by 255
The Price of Sight — Ranibizumab, Bevacizumab, and the Treatment of Macular Degeneration
Steinbrook, R. (2006) · New England Journal of Medicine · doi:10.1056/nejmp068185 · Cited by 255
Long-term outcomes of treatment of neovascular age-related macular degeneration
Gillies, M. C., Campain, A., Barthelmes, D., Simpson, J. M., Arnold, J. J., Guymer, R. H., McAllister, I. L., Essex, R. W., Morlet, N., & Hunyor, A. P. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2015.05.010 · Cited by 254
Miller, J. W. (2012) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2012.10.018 · Cited by 254
Rosenfeld, P. J., Shapiro, H., Tuomi, L., Webster, M. K., Elledge, J. A., & Blodi, B. (2010) · Ophthalmology · doi:10.1016/j.ophtha.2010.07.011 · Cited by 254
Self-citationFung, A. T.-C., Yannuzzi, L. A., & Freund, K. B. (2012) · Retina · doi:10.1097/iae.0b013e3182680a66 · Cited by 251
Khanani, A. M., Kotecha, A., Chang, A., Chen, S., Chen, Y., Guymer, R. H., Heier, J. S., Holz, F. G., Iida, T., Ives, J. A., et al. (2024) · Ophthalmology · doi:10.1016/j.ophtha.2024.02.014 · Cited by 251
Self-citationNucleic Acid Aptamers: An Emerging Tool for Biotechnology and Biomedical Sensing
Ku, T., Zhang, T., Luo, H., Yen, T., Chen, P., Han, Y., & Lo, Y. (2015) · Sensors · doi:10.3390/s150716281 · Cited by 250
A hydrogel-based stem cell delivery system to treat retinal degenerative diseases
Ballios, B. G., Cooke, M. J., van der Kooy, D., & Shoichet, M. S. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2009.12.004 · Cited by 250
Wooff, Y., Man, S. M., Aggio‐Bruce, R., Natoli, R., & Fernando, N. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01618 · Cited by 250
Fileta, J. B., Scott, I. U., & Flynn, H. W. (2014) · Ophthalmic surgery, lasers & imaging retina · doi:10.3928/23258160-20140306-08 · Cited by 249
Kim, J. E., Mantravadi, A. V., Hur, E. Y., & Covert, D. J. (2008) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2008.07.007 · Cited by 248
Intraocular Pharmacokinetics of Ranibizumab Following a Single Intravitreal Injection in Humans
Krohne, T. U., Liu, Z., Holz, F. G., & Meyer, C. H. (2012) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2012.03.047 · Cited by 246
Vascular endothelial growth factor and diabetic complications
Wirostko, B. M., Wong, T. Y., & Simó, R. (2008) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2008.09.002 · Cited by 243
Targeting VEGF-A to Treat Cancer and Age-Related Macular Degeneration
Ferrara, N., MASS, R. D., Campa, C., & Kim, R. (2006) · Annual Review of Medicine · doi:10.1146/annurev.med.58.061705.145635 · Cited by 243
Self-citationRPE transplantation and its role in retinal disease
da Cruz, L., Chen, F. K., Ahmado, A., Greenwood, J., & Coffey, P. J. (2007) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2007.07.001 · Cited by 242
Chang, T. S. (2007) · Archives of Ophthalmology · doi:10.1001/archopht.125.11.1460 · Cited by 241
Nguyen, Q. D., Das, A., Diana, V., Dugel, P. U., Gomes, A., Holz, F. G., Koh, A., Pan, C. K., Sepah, Y. J., Patel, N., et al. (2020) · Ophthalmology · doi:10.1016/j.ophtha.2019.12.031 · Cited by 241
COSCAS, G. J., Benedetto, U. D., Coscas, F., Calzi, C. I. L., Vismara, S., Roudot‐Thoraval, F., Bandello, F. M., & Souied, E. H. (2012) · Ophthalmologica · doi:10.1159/000342159 · Cited by 238
Clinical pharmacology of intravitreal anti-VEGF drugs
Fogli, S., Re, M. D., Rofi, E., Posarelli, C., Figus, M., & Danesi, R. (2018) · Eye · doi:10.1038/s41433-018-0021-7 · Cited by 238
Ranibizumab According to Need: A Treatment for Age-related Macular Degeneration
Spaide, R. F. (2007) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2007.02.024 · Cited by 237
Indocyanine Green Angiography: A Perspective on Use in the Clinical Setting
Yannuzzi, L. A. (2011) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2011.01.043 · Cited by 236
Ultrahigh-Speed Swept-Source OCT Angiography in Exudative AMD
Moult, E. M., Choi, W., Waheed, N. K., Adhi, M., Lee, B., Lu, C. D., Jayaraman, V., Potsaid, B. M., Rosenfeld, P. J., Duker, J. S., et al. (2014) · Ophthalmic surgery, lasers & imaging retina · doi:10.3928/23258160-20141118-03 · Cited by 236
Self-citationBashshur, Z. F., Haddad, Z. A., Schakal, A., Jaafar, R. F., Saab, M., & Noureddin, B. N. (2007) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2007.09.031 · Cited by 234
Gene therapy progress and prospects: RNA aptamers
Que-Gewirth, N. S., & Sullenger, B. A. (2007) · Gene Therapy · doi:10.1038/sj.gt.3302900 · Cited by 231
Shah, C. P., Garg, S. J., VANDER, J. F., Brown, G. C., Kaiser, R. S., & Haller, J. A. (2011) · Ophthalmology · doi:10.1016/j.ophtha.2011.02.034 · Cited by 231
Intravitreous anti-VEGF for diabetic retinopathy: hopes and fears for a new therapeutic strategy
Simó, R., & Hernández, C. (2008) · Diabetologia · doi:10.1007/s00125-008-0989-9 · Cited by 230
A Brief History of Anti-VEGF for the Treatment of Ocular Angiogenesis
Kim, L. A., & D'Amore, P. A. (2012) · American Journal Of Pathology · doi:10.1016/j.ajpath.2012.06.006 · Cited by 230
Bakall, B., Folk, J. C., Boldt, H. C., Sohn, E. H., Stone, E. M., Russell, S. R., & Mahajan, V. B. (2013) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2013.02.017 · Cited by 229
Heier, J. S., Kherani, S., Desai, S., Dugel, P., Kaushal, S., Cheng, S. H., Delacono, C., Purvis, A., Richards, S., Le-Halpere, A., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30979-0 · Cited by 229
Self-citationAxl is essential for VEGF‐A‐dependent activation of PI3K/Akt
Ruan, G.-X., & Kazlauskas, A. (2012) · The EMBO Journal · doi:10.1038/emboj.2012.21 · Cited by 229
Anti-VEGF Treatment Strategies for Wet AMD
Kovach, J. L., Schwartz, S. G., Flynn, H. W., & Scott, I. U. (2012) · Journal of Ophthalmology · doi:10.1155/2012/786870 · Cited by 229
Forty-Year Journey of Angiogenesis Translational Research
Cao, Y., Arbiser, J. L., D’Amato, R. J., D'Amore, P. A., Ingber, D. E., Kerbel, R. S., Klagsbrun, M., Lim, S., Moses, M. A., Zetter, B. R., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3003149 · Cited by 226
Stewart, M. W., Rosenfeld, P. J., Penha, F. M., Wang, F., Yehoshua, Z., Bueno-Lopez, E., & Lopez, P. F. (2011) · Retina · doi:10.1097/iae.0b013e31822c290f · Cited by 225
Self-citation
Metadata
- Authors
- Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y.
- Affiliations
- University of Miami (US)
- Houston Methodist (US)
- Ophthalmic Consultants of Boston (US)
- Retina Vitreous Associates Medical Group (US)
- Cleveland Clinic (US)
- Genentech (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-10-05
- Volume
- 355
- Issue
- 14
- Pages
- 1419-1431
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2124415048
- Cited by
- 5,886
- References
- 25
- Citations by year
- 2026: 179 · 2025: 231 · 2024: 207 · 2023: 198 · 2022: 242 · 2021: 324 · 2020: 311 · 2019: 259 · 2018: 286 · 2017: 325 · 2016: 313 · 2015: 356 · 2014: 358 · 2013: 371 · 2012: 371
- FWCI
- 240.91
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- University of Pennsylvania
- Pennsylvania State University
- University of South Florida
- Towson University
- Genentech
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Retinal and Macular Surgery
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Keywords
- ranibizumab, neovascular age-related macular degeneration, choroidal neovascularization, intravitreal injection, anti-VEGF therapy, VEGF-A, visual acuity, blindness prevention, endophthalmitis, uveitis, adverse events, long-term follow-up, dose comparison, occult choroidal neovascularization, anti-angiogenic therapy, VEGF inhibitors
- MeSH terms
- Ranibizumab, Aged, Aged, 80 and over, Antibodies, Monoclonal, Double-Blind Method, Female, Humans, Injections, Macular Degeneration, Male, Middle Aged, Optic Disk, Visual Acuity, Choroidal Neovascularization, Angiogenesis Inhibitors, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
